Why PDS Biotech Shares Are Jumping Today
Portfolio Pulse from Vandana Singh
PDS Biotechnology announced positive interim data from the VERSATILE-002 Phase 2 trial of PDS0101 in combination with Merck's Keytruda, in patients with HPV16-positive head and neck cancer. The 12-month overall survival rate was 87.1%, and median progression-free survival was 10.4 months. PDSB shares are up 26.96% in premarket trading.
May 26, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's Keytruda, in combination with PDS Biotech's PDS0101, showed positive interim data in the VERSATILE-002 Phase 2 trial for HPV16-positive head and neck cancer patients.
The positive interim data from the VERSATILE-002 Phase 2 trial of PDS0101 in combination with Merck's Keytruda demonstrates the potential of this combination therapy for HPV16-positive head and neck cancer patients. This news may have a positive impact on Merck's stock price in the short term, as it highlights the potential of Keytruda in combination therapies.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
PDS Biotech's positive interim data from the VERSATILE-002 Phase 2 trial of PDS0101 with Merck's Keytruda boosts PDSB shares by 26.96% in premarket trading.
The positive interim data from the VERSATILE-002 Phase 2 trial of PDS0101 in combination with Merck's Keytruda shows promising results in patients with HPV16-positive head and neck cancer. This news is likely to boost investor confidence in PDS Biotech, leading to an increase in PDSB's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100